Founded in 1978 by Kenneth Murray, Phillip Allen Sharp, Walter Gilbert, Heinz Schaller, and Charles Weissmann, Biogen Inc. is a global biotechnology leader based in Cambridge, Massachusetts. The company's core mission is to discover, develop, manufacture, and deliver innovative therapies for neurological and neurodegenerative diseases. Biogen's product portfolio includes treatments for multiple sclerosis (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA), spinal muscular atrophy (SPINRAZA), Alzheimer's disease (ADUHELM), and plaque psoriasis (FUMADERM). The company also offers biosimilars like BENEPALI and IMRALDI, focusing on markets in the United States, Europe, Asia, and beyond.

Notable figures affiliated with Biogen include founders who are prominent scientists and current key leaders such as CEO Chris Viehbacher and Chairman Caroline Dorsa. The company is publicly traded on Nasdaq under the ticker BIIB and is a component of both the Nasdaq-100 and S&P 500 indices. Biogen has achieved significant milestones, including generating a revenue of $9.836 billion and pioneering several groundbreaking therapies that have transformed patient care in neurology and immunology. Its impact is profound, providing hope and improved quality of life for millions of patients worldwide.